Claims:

1. A composition for improving allergic asthma, which comprises a *Bifidobacterium lactis* GKK2, which is deposited (No. 15205) at China General Microbiological Culture Collection Center.
2. A composition for improving allergic asthma, which comprises an active substance of the *Bifidobacterium lactis* GKK2, which is deposited (No. 15205) at China General Microbiological Culture Collection Center;.

   wherein the active substance is prepared by the following method:

   (a) Streaking lactic acid bacteria on a solid-state medium to obtain single colonies;

   (b) Inoculating a single colony of lactic acid bacteria cultured at step (a) to a liquid culture for liquid-state culture;

   (c) Centrifuging the liquid culture cultured at step (b) to obtain a bacterial pellet; and

   (d) Freeze-drying the bacterial pellet obtained at step (c);

   wherein step (b) is carried out at 30 to 50°C, in nitrogen or carbon dioxide of 0 to 1 vvm, rotate at 10 to 100 rpm, and/or incubate for 16 to 24 hours;

   wherein the temperature for the freeze-drying at step (d) is -196 to -40°C.
3. The composition of claim 1, the composition comprising an additive is selected from the group consisting of an excipient, preservative, diluent, filler, absorption enhancer, sweetener and a combination thereof.
4. The composition of claim 1, the composition being a drug, feed, drink, nutritional supplement, dairy product or health food.
5. The composition of claim 1, the composition taking the form of a powder, tablet, granule, suppository, microcapsule, ampoule/ampule or liquid spray.

6. Use of a composition comprising an active substance of *Bifidobacterium lactis* in manufacture of a medicament for treatment of allergic asthma, wherein the *Bifidobacterium lactis* is deposited (No. 15205) at China General Microbiological Culture Collection Center and the composition is as claimed in anyone of the claims 1 to 5.
7. The use of claim 6, wherein for improving allergic asthma, a subject having been administered the *Bifidobacterium lactis* GKK2 exhibits lower airway resistance than the subject having not been administered the *Bifidobacterium lactis* GKK2.
8. The use of claim 6, wherein for improving allergic asthma, a subject having been administered the *Bifidobacterium lactis* GKK2 exhibits reduced levels of non-specific IgE antibodies in serum than the subject having not been administered the *Bifidobacterium lactis* GKK2.
9. The use of claim 6, wherein for improving allergic asthma, a subject having been administered the *Bifidobacterium lactis* GKK2 exhibits reduced levels of specific IgE antibodies in serum than the subject having not been administered the *Bifidobacterium lactis* GKK2.
10. The use of claim 6, wherein for improving allergic asthma, a subject having been administered the *Bifidobacterium lactis* GKK2 exhibits less bronchoconstriction than the subject having not been administered the *Bifidobacterium lactis* GKK2.
11. The use of claim 6, wherein for improving allergic asthma, a subject having been administered the *Bifidobacterium lactis* GKK2 exhibits increased levels of GSH reductase in liver tissue interstitial fluid than the subject having not been administered the *Bifidobacterium lactis* GKK2.